Copyright
©The Author(s) 2021.
World J Gastroenterol. Jan 7, 2021; 27(1): 107-128
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.107
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.107
Table 7 Diet profile of subjects
Group | Baseline period | Ingestion day 11-20 | Ingestion day 21-30 | Ingestion day 31-40 | Ingestion day 41-60 | Ingestion day 61-80 | Ingestion day 81-100 | |
Energy (kcal) | Probiotic-treated | 1518.17 ± 484.46 | 1322.04 ± 431.90 | 1338.23 ± 376.17 | 1274.13 ± 390.37 | 1124.89 ± 378.82a | 1060.65 ± 286.86a | 1103.54 ± 311.74a |
Placebo | 1642.88 ± 599.33 | 1660.02 ± 611.62 | 1562.79 ± 1144.53 | 1396.65 ± 476.01a | 1085.16 ± 346.08a | 1047.90 ± 313.37a | 1105.73 ± 313.58a | |
Water (g) | Probiotic-treated | 744.06 ± 526.92 | 633.17 ± 397.27 | 593.60 ± 377.72 | 691.70 ± 470.44 | 720.66 ± 551.62 | 656.24 ± 419.94 | 712.81 ± 438.11 |
Placebo | 1122.19 ± 615.82 | 1016.66 ± 665.44 | 1041.80 ± 568.23 | 1100.16 ± 601.35 | 688.97 ± 533.39a | 813.86 ± 565.46 | 841.27 ± 595.64 | |
Protein (g) | Probiotic-treated | 52.72 ± 19.49 | 44.69 ± 16.73 | 46.23 ± 14.61 | 46.81 ± 12.61 | 38.49 ± 14.10a | 38.30 ± 10.23a | 39.62 ± 11.30a |
Placebo | 53.92 ± 24.02 | 55.03 ± 25.52 | 47.12 ± 33.52 | 47.02 ± 18.70 | 38.38 ± 12.95a | 35.67 ± 10.98a | 39.09 ± 9.72a | |
Lipid (g) | Probiotic-treated | 61.41 ± 30.24 | 47.15 ± 26.32 | 47.60 ± 21.41 | 49.86 ± 19.25 | 40.78±15.24a | 39.63 ± 12.02a | 40.78 ± 12.99a |
Placebo | 64.15 ± 34.36 | 63.17 ± 38.78 | 54.22 ± 36.98 | 52.15 ± 25.09a | 36.99 ± 13.85a | 36.88 ± 12.74a | 37.68 ± 9.70a | |
Carbo-hydrate (g) | Probiotic-treated | 190.85 ± 68.00 | 179.93 ± 57.44 | 180.95 ± 65.23 | 160.50 ± 59.23 | 150.80 ± 56.88 | 137.97 ± 43.53a | 144.63 ± 46.33a |
Placebo | 216.39 ± 88.21 | 221.71 ± 83.07 | 224.10 ± 190.74 | 186.27 ± 71.98 | 149.82 ± 48.91a | 144.70 ± 49.45a | 153.74 ± 60.37a | |
Fiber (g) | Probiotic-treated | 10.96 ± 5.88 | 8.66 ± 3.04 | 8.71 ± 2.91 | 8.49 ± 2.63 | 7.08 ± 2.16a | 6.24 ± 2.01a | 6.61 ± 2.48a |
Placebo | 12.17 ± 7.15 | 13.34 ± 9.00 | 11.90 ± 8.61 | 10.20 ± 4.67 | 6.96 ± 2.99a | 7.17 ± 2.30a | 7.45 ± 2.30a | |
PUFA (g) | Probiotic-treated | 16.87 ± 13.02 | 12.80 ± 7.73 | 12.17 ± 5.87 | 13.03 ± 7.64 | 12.17 ± 7.36 | 10.91 ± 4.50 | 10.86 ± 4.31 |
Placebo | 18.20 ± 13.73 | 18.49 ± 15.71 | 15.70 ± 13.47 | 16.29 ± 13.52 | 10.50 ± 5.94a | 10.03 ± 4.70a | 9.73 ± 3.1a | |
Choles-terol (mg) | Probiotic-treated | 191.39 ± 163.58 | 163.28 ± 83.55 | 168.44 ± 92.31 | 182.29 ± 68.95 | 160.32 ± 84.56 | 172.70 ± 77.78 | 179.23 ± 57.13 |
Placebo | 170.42 ± 154.32 | 168.91 ± 169.50 | 142.45 ± 159.96 | 164.19 ± 124.86 | 173.22 ± 86.80 | 165.31 ± 85.03 | 182.64 ± 81.91 |
- Citation: Rahayu ES, Mariyatun M, Putri Manurung NE, Hasan PN, Therdtatha P, Mishima R, Komalasari H, Mahfuzah NA, Pamungkaningtyas FH, Yoga WK, Nurfiana DA, Liwan SY, Juffrie M, Nugroho AE, Utami T. Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults. World J Gastroenterol 2021; 27(1): 107-128
- URL: https://www.wjgnet.com/1007-9327/full/v27/i1/107.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i1.107